A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.

Trial Details

NCT ID

NCT07459634

Phase

PHASE2

Sponsor

Jazz Pharmaceuticals

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Lurbinectedin
Durvalumab

Locations (sample)

Los Angeles, California, United States|34.05223,-118.24368
Jacksonville, Florida, United States|30.33218,-81.65565
Atlanta, Georgia, United States|33.749,-84.38798
Rock Hill, South Carolina, United States|34.92487,-81.02508

Key Eligibility Criteria

Participant has histologically or cytologically confirmed ES-SCLC (per Veterans Administration Lung Study Group staging system).
Participant has received 4 cycles of definitive platinum-based chemotherapy with durvalumab
Has Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
Must have a life expectancy of ≥ 12 weeks as assessed by the treating physician.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →